NEWTOWN, Pa., Oct. 18, 2024 – PRISM MediaWire – Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Michelle Bilski - IR Dane Andreeff - President and CO Jeff Mathiesen - CFO Conference Call Participants Anthony Vendetti - Maxim Group Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies Second Quarter 2024 Earnings Conference Call [Operator Instructions].
NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will participate in the Spring MicroCap Rodeo Conference to be held on Thursday, June 6th in NYC. Dane Andreeff, CEO, will attend the conference and plans to discuss: Pursuit of a stroke authorization in the U.S. for its Portable Neuromodulation Stimulator (PoNS®) device with the U.S. Food and Drug Administration (FDA); Helius' partnership with Lovell® Government Services to make PoNS available to federal healthcare systems, including the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD).
11 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
12 May 2025 Date | | - Cons. EPS | - EPS |
26 Mar 2025 Date | | - Cons. EPS | - EPS |
7 Nov 2024 Date | | - Cons. EPS | - EPS |
12 Aug 2024 Date | | - Cons. EPS | - EPS |
11 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
12 May 2025 Date | | - Cons. EPS | - EPS |
26 Mar 2025 Date | | - Cons. EPS | - EPS |
7 Nov 2024 Date | | - Cons. EPS | - EPS |
12 Aug 2024 Date | | - Cons. EPS | - EPS |
Medical - Devices Industry | Healthcare Sector | Dane Carl Andreeff CEO | NASDAQ (CM) Exchange | 42328V884 Cusip |
US Country | 21 Employees | - Last Dividend | 1 Jul 2025 Last Split | 27 Jun 2014 IPO Date |
Helius Medical Technologies, Inc. stands out as a pioneering company in the realm of neurotechnology with its focus straddling the development, licensing, and procurement of innovative non-implantable technologies aimed at ameliorating symptoms attributable to neurological disorders or injuries. Founded in 2014, this firm has set its base in Newtown, Pennsylvania, marking its commitment towards delivering groundbreaking solutions to enhance neurological health and function.
This avant-garde, non-surgical medical device represents Helius Medical Technologies' flagship offering. It’s specifically engineered for short-term treatment of gait deficits stemming from multiple sclerosis and balance deficits due to mild-to-moderate traumatic brain injury. A key aspect of its application involves concurrent utilization with supervised therapeutic exercises, highlighting its role as a supplementary treatment modality designed to foster improved neurological function.